| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG | Executive VP, Head of R&D | Common Shares | 52,364 | $3,272,902 | $62.50 | 06 Dec 2021 | Direct |
| iTeos Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 24,200 | 11 Jun 2024 | Direct | ||
| CRISPR Therapeutics AG | Executive VP, Head of R&D | Stock Option (Right to Buy) | 13,800 | 15 Oct 2021 | Direct | ||
| CRISPR Therapeutics AG | Executive VP, Head of R&D | Restricted Stock Units | 13,333 | 03 Dec 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ITOS | iTeos Therapeutics, Inc. | 11 Jun 2024 | 1 | $0 | 4 | Director | 13 Jun 2024, 20:00 |
| ITOS | iTeos Therapeutics, Inc. | 13 Jun 2023 | 1 | $0 | 4 | Director | 15 Jun 2023, 19:55 |
| ITOS | iTeos Therapeutics, Inc. | 09 Jun 2022 | 1 | $0 | 4 | Director | 10 Jun 2022, 19:52 |
| CRSP | CRISPR Therapeutics AG | 03 Dec 2021 | 3 | -$872,026 | 4 | Executive VP, Head of R&D | 07 Dec 2021, 19:00 |
| CRSP | CRISPR Therapeutics AG | 15 Oct 2021 | 1 | $0 | 4 | Executive VP, Head of R&D | 18 Oct 2021, 20:00 |
| ITOS | iTeos Therapeutics, Inc. | 17 Jun 2021 | 1 | $0 | 4 | Director | 21 Jun 2021, 20:21 |